Improving patient outcomes in schizophrenia: Achieving remission

Journal of Psychopharmacology

Volumn 20, Issue 6 SUPPL., 2006, Pages 57-61

  Nasrallah, Henry A ^a   Lasser, Rob ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Clinical Development   (United States)

Author keywords

Atypical antipsychotic; Long acting injectable risperidone; Patient compliance; Patient satisfaction; Remission; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

CONSENSUS; CORRELATION ANALYSIS; DISEASE SEVERITY; EMBASE; HUMAN; MEDICAL LITERATURE; MEDLINE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; SCHIZOPHRENIA; SYMPTOM;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; DELAYED-ACTION PREPARATIONS; HUMANS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; RECURRENCE; REMISSION, SPONTANEOUS; SCHIZOPHRENIA; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 33750073822     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806071248     Document Type: Review

References (51)

1. American Psychiatric Association (2004) Practice Guidelines for the Treatment of Patients with Schizophrenia. 2nd edition, www.psych.org
2. Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441-449
3. Barnes T, Curson D (1994) Long term depot antipsychotics - a risk-benefit assessment. Drug Saf 10: 464-479
4. Bilder R M, Goldman R S, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J P, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper T B, Horowitz T L, Lieberman J A (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1028
5. Burton S C (2005) Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract 11: 369-378
6. Danion J M, Rein W, Fleurot O (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156: 610-616
7. Day J C, Kinderman P, Bentall R (1998) A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 97: 93-97
8. Docherty J P, Kozma C, Grogg A, Lasser R (2002) Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. ACNP Scientific abstracts, ACNP 41st Annual Meeting, 8-12 December 2002, San Juan, Puerto Rico
9. Dolder C R, Lacro J P, Dunn L B, Jeste D V (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159: 103-108
10. Donohoe G, Owens N, O'Donnell C, Burke T, Moore L, Tobin A, O'Callaghan E (2001) Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 16: 293-298
11. Doyle A C, Pollack M H (2003) Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 64 (Suppl. 15): 40-45
12. Fakhoury W K, Wright D, Wallace M (2001) Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 16: 153-162
13. Fleischhacker W, Oehl M A, Hummer M (2003) Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 64 (Suppl. 16): 10-13
14. Frank E, Prien R F, Jarrett R B, Keller M B, Kupfer D J, Lavori P W, Rush A J, Weissman M M (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Arch Gen Psychiatry 48: 851-855
15. Gerlach J (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 9 (Suppl. 5): 17-20
16. Gharabawi G, Rodriguez S, Turkoz I, Simpson G (2005) Exploring the evidence for a relationship between symptomatic remission and functioning in patients with schizophrenia. Neuropsychopharmacology 30 (Suppl. 1): S1-S270
17. Gitlin M, Nuechterlain K, Subotnik K, Ventura J, Minz J, Fogelson D L, Bartzokis G, Aravagiri M (2001) Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 158: 1835-1842
18. Green M F, Barnes T R, Danion J M, Gallhofer B, Meltzer H Y, Pantelis C (2005) The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia. Schizophr Res 74: 253-261
19. Harvey P D, Green M F, McGurk S R, Meltzer H Y (2003) Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl). 169: 404-411
20. Ho B C, Andreasen N C, Flaum M, Nopoulos P, Miller D (2000) Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry 157: 808-815
21. Jones R, Docherty J, Turkoz I, Lasser R (2004) Manual-guided use of long-acting risperidone in community-based settings. Poster presented at the 44th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), June 1-4, 2004, Phoenix, AZ, USA
22. Kane J (2001) Progress defined - short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 16 (Suppl. 1): S1-S8
23. Kane J (2004) For whom and when a long-acting injectable atypical antipsychotic might be appropriate. J Clin Psychiatry 65: 122-125
24. Kane J M (1996) Schizophrenia. N Engl J Med 334: 34-41
25. Kane J M (2003) Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 64 (Suppl. 16): 34-40
26. Kane J M, Aguglia E, Altamura A C, Ayuso Gutierrez J L, Brunello N, Fleischhacker W W, Gaebel W, Gerlach J, Guelfi J D, Kissling W, Lapierre Y D, Lindstrom E, Mendlewicz J, Racagni G, Carulla L S, Schooler N R (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8: 55-66
27. Keith S J, Kane J M (2003) Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64: 1308-1315
28. Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, Llorca P M (2005) Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 19: 15-21
29. Lacro J P, Dunn L B, Dolder C R, Leckband S G, Jeste D V (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63: 892-909
30. Lasser R A, Bossie C A, Gharabawi G M, Kane J M (2005) Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 77: 215-227
31. Lieberman J A (1996) Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 57 (Suppl. 11): 68-71
32. Lieberman J A, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer R M (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28: 995-1003
33. Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, Keefe R S, Davis S M, Davis C E, Lebowitz B D, Severe J, Hsiao J K (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
34. Lindenmayer J P, Jarboe K, Bossie C A, Zhu Y, Mehnert A, Lasser R (2005) Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 20: 213-221
35. Marder S R (2000) Integrating pharmacological and psychosocial treatments for schizophrenia. Acta Psychiatr Scand Suppl 407: 87-90
36. Nasrallah H, Duchesne I, Mehnert A, Janagap C (2004) Health-related quality of life with schizophrenia during treatment with long-acting risperidone injection. J Clin Psychiatry 65: 531-536
37. Nierenberg A A, DeCecco L M (2001) Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 62 (Suppl. 16): 5-9
38. Packer S, Husted J, Cohen S, Tomlinson G (1997) Psychopathology and quality of life in schizophrenia. J Psychiatry Neurosci 22: 231-234
39. Patel M X, Nikolaou V, David A S (2003) Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychological Medicine 33: 83-89
40. Patel M X, De Zoysa N, Baker D, David A S (2005) Antipsychotic depot medication and attitudes of community psychiatric nurses. J of Psychiatric and Mental Health Nursing 12: 237-244
41. Perkins D O (2002) Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: 1121-1128
42. Peuskens J (2004) Clinical effectiveness in adults with chronic schizophrenia. Eur Neuropsychopharmacol 14 (Suppl. 4): S453-S459
43. Revicki D A, Genduso L A, Hamilton S H, Ganoczy D, Beasley Jr C M (1999) Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 8: 417-426
44. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y (2004) Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 24: 582-591
45. Robinson D, Woerner M G, Alvir J M, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman J A (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247
46. Taylor M, Chaudhry I, Cross M, McDonald E, Miller P, Pilowsky L, Strickland P (2005) Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol 20: 175-181
47. Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A, Vazquez-Barquero J L (2004) The personal impact of schizophrenia in Europe. Schizophr Res 69: 125-132
48. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis J P A, Volavka J, Haukka J (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333: 224
49. Van Dinter R, Hovens J, Roman B (2006) Choosing a form of antipsychotic medication. Poster presented at the 13th Biennial Winter Workshop on Schizophrenia Research, 4-10 February 2006, Davos, Switzerland
50. Volavka J, Czobor P, Sheitman B, Lindenmayer J P, Citrome L, McEvoy J P, Cooper T B, Chakos M, Lieberman J A (2002) Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159: 255-262
51. Walburn J, Gray R, Gournay K, Quraishi S, David A S (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179: 300-307